Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rajkumar, S. Vincent, Hayman, Suzanne R., Lacy, Martha Q., Dispenzieri, Angela, Geyer, Susan M., Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji, Greipp, Philip R., Fonseca, Rafael, Lust, John A., Russell, Stephen J., Kyle, Robert A., Witzig, Thomas E., Gertz, Morie A.
Formato: Artigo
Idioma:Inglês
Publicado: © 2005 by The American Society of Hematology 2005
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895238/
https://ncbi.nlm.nih.gov/pubmed/16118317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-07-2817
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares